New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

HealthDay News — For patients with systemic lupus erythematosus (SLE), obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, is superior to placebo, according to a study published ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Phase III results put obinutuzumab in line for approval ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

A new study found statin use is associated with reduced disease activity and inflammation in people with systemic lupus erythematosus (SLE), particularly in patients younger than 40 years.

Johnson & Johnson has won U.S. Food and Drug Administration fast-track designation for its investigational nipocalimab drug in adults with systemic lupus erythematosus, a chronic autoimmune disease.

Please provide your email address to receive an email when new articles are posted on . Patients with systemic lupus with a history of skin rashes are likely to have high interferon levels. This ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Maureen McMahon, ...

Investigators assessed shear wave elastography (SWE) in detecting subclinical renal damage in patients with LN currently in clinical remission.